Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL380 Target Snapshot

Human immunodeficiency virus 2 · ORGANISM · Human immunodeficiency virus 2

4,266Compounds
428Assays
44Approved Drugs
4,708.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Human immunodeficiency virus 2 as ChEMBL target CHEMBL380. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Human immunodeficiency virus 2
ORGANISM · Human immunodeficiency virus 2
As of 2026-09-13
ChEMBL target ID
CHEMBL380
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Human immunodeficiency virus 2 still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelHuman immunodeficiency virus 2
UniProt AccessionN/A

Human immunodeficiency virus 2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Human immunodeficiency virus 2.

Review nameHuman immunodeficiency virus 2
OrganismHuman immunodeficiency virus 2
Clinical Profile

Clinical Phase Distribution

44
Approved
7
Phase III
6
Phase II
Assay Mix

Activity Type Distribution

IC50774.0
KI2.0
EC503,932.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL57548 10.97 IC50 0.01071 Preclinical
CHEMBL513181 10.74 EC50 0.018 Preclinical
CHEMBL5398494 10.74 EC50 0.018 Preclinical
CHEMBL267571 10.64 Ki 0.023 Preclinical
CHEMBL104245 10.44 EC50 0.036 Preclinical
CHEMBL291331 9.99 IC50 0.1016 Preclinical
CHEMBL13134 9.89 Ki 0.13 Clinical
CHEMBL5193766 9.85 EC50 0.14 Preclinical
CHEMBL299704 9.85 IC50 0.1429 Preclinical
CHEMBL114 9.7 EC50 0.2 Approved
Distribution

pChEMBL Value Distribution

276
5.0
210
5.5
253
6.0
171
6.5
178
7.0
98
7.5
95
8.0
27
8.5
11
9.0
23
9.5
pChEMBL
Approved Drugs

Approved Drugs

DOLUTEGRAVIR SODIUM
CHEMBL1213165
Approved 2013
TOFACITINIB
CHEMBL221959
Approved 2012
ELVITEGRAVIR
CHEMBL204656
Approved 2012
RUXOLITINIB
CHEMBL1789941
Approved 2011
INGENOL MEBUTATE
CHEMBL1863513
Approved 2010
PLERIXAFOR
CHEMBL18442
Approved 2008
ETRAVIRINE
CHEMBL308954
Approved 2008
RALTEGRAVIR
CHEMBL254316
Approved 2007
RALTEGRAVIR POTASSIUM
CHEMBL518520
Approved 2007
DARUNAVIR
CHEMBL1323
Approved 2006
TIPRANAVIR
CHEMBL222559
Approved 2005
EMTRICITABINE
CHEMBL885
Approved 2003
ENFUVIRTIDE
CHEMBL525076
Approved 2003
ATAZANAVIR
CHEMBL1163
Approved 2003
ADEFOVIR DIPIVOXIL
CHEMBL922
Approved 2002
TENOFOVIR DISOPROXIL
CHEMBL1538
Approved 2001
TENOFOVIR DISOPROXIL FUMARATE
CHEMBL1486
Approved 2001
LOPINAVIR
CHEMBL729
Approved 2000
AMPRENAVIR
CHEMBL116
Approved 1999
EFAVIRENZ
CHEMBL223228
Approved 1998
NELFINAVIR
CHEMBL584
Approved 1997
RITONAVIR
CHEMBL163
Approved 1996
LAMIVUDINE
CHEMBL141
Approved 1995
SAQUINAVIR
CHEMBL114
Approved 1995
STAVUDINE
CHEMBL991
Approved 1994
ZALCITABINE
CHEMBL853
Approved 1992
ZIDOVUDINE
CHEMBL129
Approved 1987
Assay Landscape

Assay Landscape

428
Total Assays
1,068
Tested Compounds
1
Assay Types
Functional — 428 assays, 1,068 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 419 1,063 6.1
cell-based format 7 4 5.2
assay format 2 1 5.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine